Loading...
  • therapy
  • Like any combination cancer treatment, especially in very sick patients who have failed prior therapy, the IL-21 and sorafenib in tandem have side effects. (xconomy.com)
  • A total of 439 patients, who were considered to have recovered from their symptoms following therapy on the NHS, took part in the study. (medicalnewstoday.com)
  • For Arm A: patients must be at first recurrence of GBM, must not have had previous anti-VEGF therapy, and must be candidates for surgical partial or gross-total resection. (knowcancer.com)
  • For Arm B: patients must be at first recurrence of GBM and must not have had prior anti-VEGF therapy. (knowcancer.com)
  • Patients must have sufficient time to recover from prior therapy. (knowcancer.com)
  • After three courses, objective tumor response was assessed, and responding patients were allowed to receive consolidation with high-dose therapy/stem cell transplant if eligible, or to continue for a maximum of six courses. (cancernetwork.com)
  • I. To characterize safety and drug-related adverse events of two doses (15 and 25 mg) of intravenous weekly temsirolimus combined with short term complete androgen ablation and to select a favorable and tolerable dose for prostate cancer patients who experience biochemical failure after prostatectomy and/or radiation therapy. (knowcancer.com)
  • Patients receive combined androgen ablation therapy comprising a luteinizing hormone-releasing hormone analogue (i.e., leuprolide acetate intramuscularly once monthly or goserelin subcutaneously every 3 months) and an oral anti-androgen drug (i.e., bicalutamide or nilutamide once daily or flutamide 3 times daily) on days 1-90. (knowcancer.com)
  • Beginning on day 60 of hormonal therapy, patients receive temsirolimus IV over 30 minutes once weekly. (knowcancer.com)
  • NOTE: *Patients may receive no more than 3 months of hormonal therapy, including therapy initiated within 2 months of study entry. (knowcancer.com)
  • indolent
  • Dec. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. announced today that in a pivotal study of patients with indolent non-Hodgkin's lymphoma (NHL), whose disease has progressed during or following treatment with rituximab, TREANDA (bendamustine HCl) induced a high rate of response. (drugs.com)
  • According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment. (drugs.com)
  • The high response rate in this study suggest that bendamustine could offer substantial periods of remission to patients with indolent NHL whose cancer is progressing after treatment with rituximab," said Brad Kahl, MD, Associate Professor, Director Lymphoma Service, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, and the lead investigator of this study. (drugs.com)
  • In this pivotal study of 100 patients with indolent NHL whose disease has progressed during or following treatment with rituximab, or a rituximab- containing regimen, as assessed by an independent radiological committee, 75 patients had a response. (drugs.com)
  • The Phase 3, multicenter, single-arm study evaluated the efficacy and safety of single-agent bendamustine in 100 patients with indolent NHL whose disease has progressed during or following treatment with rituximab. (drugs.com)
  • In addition, Cephalon has completed a phase 2 study with TREANDA in combination with rituximab in patients with relapsed indolent and mantle cell NHL. (drugs.com)
  • Patients are stratified according to histologic subtype (indolent vs aggressive). (knowcancer.com)
  • disease
  • So even though sorafenib and Pfizer's sunitinib (Sutent) have brought progress to patients with this disease, there's always room for improvement. (xconomy.com)
  • Patients with recurrent disease whose diagnostic pathology confirmed glioblastoma will not need re-biopsy. (knowcancer.com)
  • All patients who show a continued response or stable disease without major side effects may continue to receive liposomal vincristine for up to 24 months. (knowcancer.com)
  • For patients with measurable disease after debulking: best overall response distribution (BOR), objective response rate (PR+CR), complete response rate and duration of response (DOR). (clinicaltrials.gov)
  • Determine the objective response rate and disease-stabilization rate in patients with relapsed or refractory multiple myeloma treated with R115777. (knowcancer.com)
  • Determine whether the presence of activating RAS mutations in myeloma cells correlates with disease response in patients treated with this drug. (knowcancer.com)
  • Dr. Younes reported that the paclitaxel/topotecan regimen produced an overall response rate of 27% in 15 patients with primary refractory disease, including two partial remissions and two complete remissions. (cancernetwork.com)
  • The combination produced an overall response rate of 72% in 18 patients with relapsed disease, including 12 partial remissions and one complete remission. (cancernetwork.com)
  • ErbB4 may play a role in the proliferation of oligodendrocyte progenitor cells, differentiation of oligodendrocytes, and remyelination, and, therefore, the reduced ErbB4 expression in immune cells of patients with RR-MS may contribute to insufficient remyelination that occurs in the disease. (hindawi.com)
  • Patients are stratified according to disease type. (clinicaltrials.gov)
  • treatment
  • Bortezomib, the first of a new class of drugs called proteasome inhibitors, produced a 35% response rate in patients with relapsed, refractory multiple myeloma, an unusually high rate in these patients, for whom there is no other treatment. (bmj.com)
  • Over half of these were found to have suffered a relapse event, with up to 79 per cent of events occurring within the first six months after treatment. (medicalnewstoday.com)
  • Patients with residual depression symptoms at the end of treatment were twice as likely to relapse. (medicalnewstoday.com)
  • Dr Jaime Delgadillo, from the University of Sheffield, said: "These findings underline the importance of monitoring patients' wellbeing for at least six months after treatment and offering adequate support to ensure they stay well. (medicalnewstoday.com)
  • Incomplete or insufficient treatment also costs the NHS, as patients who relapse often need further care or support. (medicalnewstoday.com)
  • The investigators hypothesize that the LFA3-CD2 co-stimulatory pathway play an important role in the immune pathogenesis of AA and treatment with Alefacept can help treat refractory/relapsed cases of AA. (clinicaltrials.gov)
  • After completion of the 12 week treatment, patients will go through a 12 week observation period. (clinicaltrials.gov)
  • Patients are then randomized to 1 of 2 treatment arms. (knowcancer.com)
  • Before and during the treatment patients will have exams done. (knowcancer.com)
  • Since Liposomal Vincristine may prevent the body from making and/or keeping new blood cells, prior to treatment patients will also have a Human Immunodeficiency Virus (AIDS virus) test, a blood test to detect the presence of antibodies to the AIDS virus. (knowcancer.com)
  • Female patients may also be required to have a urine pregnancy test before treatment may begin, as it is not known how the drug may affect the unborn child. (knowcancer.com)
  • Patients who achieved at least a partial remission after three courses of treatment were allowed to cross over and receive high-dose chemotherapy/transplant, so many patients did not receive the full six courses of chemotherapy. (cancernetwork.com)
  • Because many patients with NHL eventually become resistant to treatment with rituximab and other therapies, new treatments are always required. (drugs.com)
  • Of those patients who responded to treatment, 14 had a complete response and three had an unconfirmed complete response. (drugs.com)
  • prognosis
  • The physician should acknowledge and discuss with the patient that uncertainty exists about the prognosis and the consequences of recurrent seizure. (acpjc.org)
  • cancer
  • We continue to see promising anti-tumor effects from the combination of IL-21 and Nexavar in patients with renal cell cancer," said Nicole Onetto, ZymoGenetics' chief medical officer, in a company statement. (xconomy.com)
  • To determine the ability of sargramostim (GM-CSF) to increase the number and activation of dendritic cells (DC) in patients with biochemically relapsed prostate cancer. (knowcancer.com)
  • To determine whether sargramostim administration generates antiprostate cancer immune responses in these patients. (knowcancer.com)
  • Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review. (bioportfolio.com)
  • days
  • Patients received bendamustine 120 mg per meters squared intravenously over 60 minutes on days one and two every 21 days for six cycles. (drugs.com)
  • To estimate the MTD or RPTD of aflibercept administered intravenously every 21 days in these patients. (knowcancer.com)
  • determine
  • To determine the risk for relapse at 1 and 2 years after discontinuation of antiepileptic drugs, and the association of 3 clinical factors with the risk for relapse in patients with epilepsy. (acpjc.org)
  • To determine the effect of administration schedule and hormonal state on sargramostim-induced DC number and activation in these patients. (knowcancer.com)
  • Determine whether the degree of inhibition of FTase activity and farnesylation of lamin-B, H-RAS, K-RAS, and N-RAS in peripheral blood mononuclear cells (PBMC) and tumor tissue correlates with tumor response in patients treated with this drug. (knowcancer.com)
  • correlate
  • The presence of a Paroxysmal Nocturnal Hemoglobinuria (PNH) clone in patients with AA has been shown to correlate with increased response to immunosuppression25. (clinicaltrials.gov)
  • Correlate R115777 plasma levels, degree of farnesylation inhibition in PBMC and tumor tissue, and RAS mutation status with tumor response in patients treated with this drug. (knowcancer.com)
  • least
  • Patients must have at least 15 unstained slides or 1 tissue block (frozen or paraffin embedded) available from a prior biopsy or surgery. (knowcancer.com)